VIR BIOTECHNOLOGY INC's ticker is VIR and the CUSIP is 92764N102. A total of 119 filers reported holding VIR BIOTECHNOLOGY INC in Q3 2020. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,680 | -92.3% | 28,461 | -79.7% | 0.00% | -100.0% |
| Q2 2023 | $3,443,644 | +279.7% | 140,385 | +260.2% | 0.00% | – |
| Q1 2023 | $906,948 | +237.5% | 38,975 | +267.1% | 0.00% | – |
| Q4 2022 | $268,742 | -80.8% | 10,618 | -85.4% | 0.00% | -100.0% |
| Q3 2022 | $1,400,000 | +579.6% | 72,612 | +796.1% | 0.00% | – |
| Q2 2022 | $206,000 | -97.8% | 8,103 | -97.7% | 0.00% | -100.0% |
| Q1 2022 | $9,245,000 | -51.9% | 359,421 | -21.8% | 0.00% | -57.1% |
| Q4 2021 | $19,238,000 | +196.9% | 459,458 | +208.6% | 0.01% | +133.3% |
| Q3 2021 | $6,480,000 | +25.7% | 148,871 | +36.5% | 0.00% | +50.0% |
| Q2 2021 | $5,155,000 | -35.6% | 109,045 | -30.2% | 0.00% | -50.0% |
| Q1 2021 | $8,009,000 | +130.5% | 156,200 | +20.4% | 0.00% | +100.0% |
| Q4 2020 | $3,475,000 | -26.9% | 129,779 | -6.3% | 0.00% | -33.3% |
| Q3 2020 | $4,755,000 | -13.4% | 138,524 | +3.4% | 0.00% | -40.0% |
| Q2 2020 | $5,488,000 | – | 133,926 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bill & Melinda Gates Foundation | 1,559,142 | $40,100,000 | 21.56% |
| SB INVESTMENT ADVISERS (UK) LTD | 22,216,644 | $571,412,000 | 2.71% |
| Nan Fung Group Holdings Ltd | 210,563 | $5,416,000 | 2.57% |
| Taikang Asset Management (Hong Kong) Co Ltd | 533,332 | $13,717,000 | 2.34% |
| Crawford Lake Capital Management, LLC | 168,200 | $4,326,000 | 1.80% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 126,900 | $3,264,000 | 1.75% |
| Zebra Capital Management LLC | 22,227 | $572,000 | 1.31% |
| Alaska Permanent Fund Corp | 2,300,000 | $59,156,000 | 0.98% |
| CLARK ESTATES INC/NY | 180,000 | $4,630,000 | 0.73% |
| Temasek Holdings (Private) Ltd | 5,602,553 | $144,097,663 | 0.61% |